Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY - FEDBIZOPPS ISSUE OF JULY 27, 2016 FBO #5360
SOURCES SOUGHT

Q -- RNA Extraction

Notice Date
7/25/2016
 
Notice Type
Sources Sought
 
NAICS
541990 — All Other Professional, Scientific, and Technical Services
 
Contracting Office
Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6001 Executive Boulevard, Room 3155, MSC 9593, Bethesda, Maryland, 20892, United States
 
ZIP Code
20892
 
Solicitation Number
HHS-NIH-NIDA-SSSA-SS-2016-487
 
Archive Date
8/19/2016
 
Point of Contact
Stacey M Polk,
 
E-Mail Address
spolk@nida.nih.gov
(spolk@nida.nih.gov)
 
Small Business Set-Aside
N/A
 
Description
Description: RNA Extraction from Canine Tissue Samples This is a Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of all qualified sources to perform a potential requirement. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Background: The NIH Comparative Oncology Program has a collection of cancer tissue samples from dogs that span five different histologies (mast cell tumor, hemangiosarcoma, soft tissue sarcoma, pulmonary tumor, osteosarcoma, lymphoma, and melanoma) with anywhere from ~100-500 patients (dogs) per histology. Each patient has tumor and normal tissue, serum, plasma, whole blood, and urine. Tissue samples are flash-frozen, in OCT, and formalin-fixed. All patients are treatment-naïve and have clinical outcome data (e.g. Were they treated for their cancer, and if so, with what treatment regime and what happened to them?). The biological material however needs to be supplemented with transcriptomic data. The service requested is to extract RNA from the tissue samples. The extracted RNA will then be identified using RNA-Seq experiments. This will provide information on underlying molecular level details (RNA transcript identifiers) associated with the various canine cancers. Additional bioinformatics analysis by NCATS, will add focused information on gene groups (modules), biochemical pathways, and controlling transcription factors relevant to each canine cancer state. Similar analysis on publically available human data will allow us to find gene modules common to both canine and human cancers. Purpose and Objectives: The purpose of this contract is to provide means for identifying cancer diagnostic biomarkers and drug repurposing hypotheses that can be used to guide future validation experiments in canines and humans. Project Requirements: Contractor Requirements: The contractor will provide the following: The vendor will receive 75 canine tissue samples from our collaborators at the National Cancer Institute (NCI), Center for Cancer Research (CRC), Comparative oncology program (COP). The vendor will analyze the tissue samples for integrity of genetic material and extract RNA. The vendor will then provide 2 ug of RNA extracted from each of the 75 canine tissue samples to a selected Gene Sequencing Laboratory (GSL). Vendor will send to a selected Gene Sequencing Laboratory 2 ug /sample RNA (150 ug altogether), extracted from each of 75 samples which include: Osteosarcoma: 12 tumor samples and 3 matched normal controls T cell lymphoma: 12 tumor samples and 3 matched normal controls Pulmonary neoplasms: 12 tumor samples and 3 matched normal controls B cell lymphoma: 12 tumor samples and 3 matched normal controls Melanoma: 12 tumor samples and 3 matched normal controls Anticipated Period of Performance/Delivery Date: The period of performance for all requirements should be no longer than 12 weeks after receipt of tissue samples by the vendor from the National Cancer Institute, and services are considered complete once the 2 ug/sample of RNA is provided to a selected Gene Sequencing Laboratory (GSL). Capability statement /information sought. Contractors that believe they possess the ability to provide the requirement should submit documentation of their ability to meet each of the project requirements to the Contract Specialist. The response should directly and specifically state in the, capabilities statement, which project requirements you can supply. Contractors must also provide their Company Name, DUNS Number, Physical Address, Point of Contact, and Size and Type of Business (e.g., 8(a), HubZone, etc.) pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. The information submitted must be must be in an outline format that addresses each of the elements of the project requirement and in the capability statement /information sought paragraphs stated herein. The response must include the respondents' technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses. All responses (capability statements) sent in response to this Small Business Sources Sought Notice must be submitted electronically (via e-mail) to the Contract Specialist. Facsimile responses are NOT accepted. The response must be submitted to Stacey Polk, Contract Specialist at spolk@nida.nih.gov. The response must be received on or before August 4, 2016, 2016 at 10am, Eastern Standard Time. "Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s)."
 
Web Link
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-01/HHS-NIH-NIDA-SSSA-SS-2016-487/listing.html)
 
Place of Performance
Address: National Institutes of Health, 9800 Medical Center Drive, Bethesda, Maryland, 20850, United States
Zip Code: 20850
 
Record
SN04195428-W 20160727/160726000623-b6befb692a3792044f3cc59d087c74f5 (fbodaily.com)
 
Source
FedBizOpps Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  © 1994-2020, Loren Data Corp.